XML 26 R12.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
Our policies for managing risk related to foreign currency, interest
rates, credit and markets and our process for determining fair
value have not changed from those described in our Annual
Report on Form 10-K for 2024.
In the six months 2025 we assumed contingent consideration
liabilities with a fair value of $90 related to previous acquisitions
made by Inari Medical Inc. (Inari). Refer to Note 7 for further
information on the acquisition of Inari.
In 2024 we recorded $208 of contingent consideration related to
various acquisitions described in Note 7.
There were no significant transfers into or out of any level of the
fair value hierarchy in 2025.
Assets Measured at Fair Value
June 30
December 31
2025
2024
Cash and cash equivalents
$2,375
$3,652
Short-term investments
—
750
Trading marketable securities
286
259
Level 1 - Assets
$2,661
$4,661
Available-for-sale marketable securities:
Corporate and asset-backed debt securities
$50
$53
United States agency debt securities
—
1
United States treasury debt securities
37
34
Certificates of deposit
2
3
Total available-for-sale marketable securities
$89
$91
Foreign currency exchange forward contracts
54
225
Level 2 - Assets
$143
$316
Total assets measured at fair value
$2,804
$4,977
Liabilities Measured at Fair Value
June 30
December 31
2025
2024
Deferred compensation arrangements
$286
$259
Level 1 - Liabilities
$286
$259
Foreign currency exchange forward contracts
$297
$77
Level 2 - Liabilities
$297
$77
Contingent consideration:
Beginning
$452
$289
Additions
90
208
Change in estimate and foreign exchange
5
8
Settlements
(76)
(53)
Ending
$471
$452
Level 3 - Liabilities
$471
$452
Total liabilities measured at fair value
$1,054
$788
Fair Value of Available for Sale Securities by Maturity
June 30
December 31
2025
2024
Due in one year or less
$48
$47
Due after one year through three years
$41
$44
On June 30, 2025 and December 31, 2024 the aggregate
difference between the cost and fair value of available-for-sale
marketable securities was nominal. Interest income on cash and
cash equivalents and short-term investments and income from
marketable securities was $24 and $26 in the three months 2025
and 2024, and $62 in the six months 2025 and 2024, which was
recorded in other income (expense), net.
Our investments in available-for-sale marketable securities had a
minimum credit quality rating of A2 (Moody's), A (Standard &
Poor's) and A (Fitch). We do not plan to sell the investments, and
it is not more likely than not that we will be required to sell the
investments before recovery of their amortized cost basis, which
may be maturity.